Clinical trial · Interventional
A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Surgical resection of the affected liver offers the best chance for disease-free survival in patients with Hepatoma (HCC). Unfortunately, most hepatoma patients present with disease which is multi-focal and thus not resectable. Fewer than 15% of HCC patients are resectable. The objective of treatment with TheraSphere is to selectively administer a dose of radioactive material directly to neoplastic tissue in the liver. Systemic therapy is largely ineffective.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brachytherapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Efficacy
- measure
- - Response to treatment
- measure
- - Survival time from treatment
- measure
- Safety:
- measure
- - Adverse experience
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Over 18 years of age of any sex, race * Histological proof of HCC * Able to give Informed Consent * ECOG performance equal or less than 2 * Life expectancy equal to or greater than 3 months * Non- pregnant with acceptable contraception in premenopausal women * Greater than 4 weeks since prior radiation therapy or surgery * 1 month post chemotherapy * Serum Bilirubin \< 2.0 * Acceptable white blood count Exclusion Criteria: * Co-morbid disease that would place patient at undue risk. * Pre-existing diarrhea/illness * Pregnant * Fail preliminary MAA testing
References
Publications (0)
Data not yet available